Conditions: Chronic Hepatitis C Virus (HCV) Infection
Keywords: Treatment-naïve HCV Gentoype 2 Non-cirrhotic Chronic Hepatitis C HCV Gentoype 5 HCV Gentoype 4 HCV Gentoype 6 HCV Gentoype 1 Compensated cirrhotic Treatment-experienced HCV Gentoype 3
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 104
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment with the ABT-493/ABT-530 combination regimen in adults with chronic HCV genotype 1 - 6 infection and chronic severe renal impairment.

Detailed description:

Arms:
arm 1: ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.

Interventions: intervention 1: ABT-493/ABT-530
Intervention descriptions: intervention 1: Tablet; ABT-493 coformulated with ABT-530

Protocol document: